Pharmacogenomics in the Intensive Care Unit: Focus on Potential Implications for Clinical Practice

Author(s): John M. Allen, Shyam Gelot

Journal Name: Recent Patents on Biotechnology

Volume 8 , Issue 2 , 2014

Become EABM
Become Reviewer


Critically ill patients often are at high-risk for adverse drug reactions (ADRs), mainly due to alterations in pharmacokinetic and pharmacodynamic (PK/PD) parameters. These PK/PD differences in can also lead to inadequate therapeutic response to many commonly used drugs in this patient population. Frequently in the critically ill patient, medications are utilized based on a “trial-and-error” approach. Furthermore, drug dosing in the critically ill largely remains a “one-size-fits-all” phenomenon, utilizing dosing based on PK studies in healthy volunteers. Known differences in gene variation among the general population can greatly alter response to drug therapy. The use of pharmacogenomics (PGX) to aid in the development of individualized pharmacotherapeutic regimens, potentially may reduce ADRs and increase therapeutic efficacy. Potential uses of PGX include: identification of patients who are particularly susceptible to ADRs; and patients whom are more likely to benefit from a particular drug therapy, based on the patient’s own genetic profile. This review will focus on potential applications of PGX in the critically ill, including management of acute coronary syndromes (ACS), invasive fungal infections, and pain management. Current barriers to PGX-guided therapy in the critically ill and recent patent developments in the clinical application of PGX will also be discussed.

Keywords: Acute coronary syndromes, critical care, ICU, invasive fungal infections, pain management, pharmacogenomics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [116 - 122]
Pages: 7
DOI: 10.2174/1872208309666140904111139

Article Metrics

PDF: 77